Terms: = Ovarian cancer AND B2M, P61769, 567, ENSG00000166710 AND Treatment
18 results:
1. Genetically engineered neural stem cells expressing cytosine deaminase and interferon-beta enhanced T cell-mediated antitumor immunity against gastric cancer in a humanized mouse model.
Choi Y; Lee HK; Ahn D; Nam MW; Go RE; Choi KC
Life Sci; 2023 Sep; 328():121866. PubMed ID: 37331506
[TBL] [Abstract] [Full Text] [Related]
2. Differences between complex epithelial neoplasms of the ovary and high-grade serous ovarian cancer: a retrospective observational cohort study.
Li X; Ding Y; Liu Y; Yang M
J Ovarian Res; 2022 Dec; 15(1):125. PubMed ID: 36456989
[TBL] [Abstract] [Full Text] [Related]
3. Prediction of homologous recombination deficiency from cancer gene expression data.
Kang J; Lee J; Lee A; Lee YS
J Int Med Res; 2022 Nov; 50(11):3000605221133655. PubMed ID: 36380518
[TBL] [Abstract] [Full Text] [Related]
4. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract] [Full Text] [Related]
5. Optimized Biobanking Procedures for Preservation of RNA in Tissue: Comparison of Snap-Freezing and RNAlater-Fixation Methods.
Hentze JL; Kringelbach TM; Novotny GW; Hamid BH; Ravn V; Christensen IJ; Høgdall C; Høgdall E
Biopreserv Biobank; 2019 Dec; 17(6):562-569. PubMed ID: 31618057
[No Abstract] [Full Text] [Related]
6. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832
[TBL] [Abstract] [Full Text] [Related]
7. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract] [Full Text] [Related]
8. Estimating Cost-effectiveness of a Multimodal ovarian cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of ovarian cancer Screening (UKCTOCS).
Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
[TBL] [Abstract] [Full Text] [Related]
9. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
Siebenkäs C; Chiappinelli KB; Guzzetta AA; Sharma A; Jeschke J; Vatapalli R; Baylin SB; Ahuja N
PLoS One; 2017; 12(6):e0179501. PubMed ID: 28622390
[TBL] [Abstract] [Full Text] [Related]
10. Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.
Petretto A; Carbotti G; Inglese E; Lavarello C; Pistillo MP; Rigo V; Croce M; Longo L; Martini S; Vacca P; Ferrini S; Fabbi M
Oncotarget; 2016 Nov; 7(45):72518-72536. PubMed ID: 27683036
[TBL] [Abstract] [Full Text] [Related]
11. The Role of Knowledge on Genetic Counseling and Testing in Black cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation.
Hurtado-de-Mendoza A; Jackson MC; Anderson L; Sheppard VB
J Genet Couns; 2017 Feb; 26(1):113-121. PubMed ID: 27402168
[TBL] [Abstract] [Full Text] [Related]
12. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial cancer.
Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
[TBL] [Abstract] [Full Text] [Related]
13. The clinical impact of gynecologic MRI.
Ratner ES; Staib LH; Cross SN; Raji R; Schwartz PE; McCarthy SM
AJR Am J Roentgenol; 2015 Mar; 204(3):674-80. PubMed ID: 25714302
[TBL] [Abstract] [Full Text] [Related]
14. treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study.
Rafii A; Deval B; Geay JF; Chopin N; Paoletti X; Paraiso D; Pujade-Lauraine E
Int J Gynecol Cancer; 2007; 17(4):777-83. PubMed ID: 17367318
[TBL] [Abstract] [Full Text] [Related]
15. ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract] [Full Text] [Related]
16. treatment strategies of the borderline ovarian tumors.
Bulletti C; Albonetti A; Talamo T; Reggiani LB; Giacomucci E; Alfieri S; Flamigni C
Front Biosci; 1996 Dec; 1():g12-3. PubMed ID: 9159260
[TBL] [Abstract] [Full Text] [Related]
17. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract] [Full Text] [Related]
18. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
[TBL] [Abstract] [Full Text] [Related]
